Danny Rischin

32.4k citations
377 papers · 15.6k · 8 hit papers · h-index 57

Impact in

    • Head and Neck Cancer Studies
  • Oncology top 0.2%
    • HER2/EGFR in Cancer Research
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Research Studies

Papers in

    • Cancer Immunotherapy and Biomarkers 53
    • CAR-T cell therapy research 28
    • Cancer Diagnosis and Treatment 24
    • Head and Neck Cancer Studies 106

Danny Rischin

356 papers receiving 15.3k citations

Danny Rischin's Hit Papers

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study 2025 · 12 citations
120+8+16Years since publication50010001.5k2.0k

Peers

Danny Rischin
Comparison fields: 5 of 145
  • Otorhinolaryngology 3.2k
  • Oncology 5.7k
  • Pulmonary and Respiratory Medicine 4.6k
  • Cancer Research 1.8k
  • Radiology, Nuclear Medicine and Imaging 1.5k
Replace Jacek Jassem with:
Jacek Jassem Poland
M. van Glabbeke Belgium
Lalitha Shankar United States
Jan Bogaerts Belgium
Roger B. Cohen United States
Stephen J. Gwyther United Kingdom
Lester J. Peters United States
P. Therasse Belgium
Margaret Mooney United States
Corey J. Langer United States
Danny Rischin relative to Jacek Jassem Poland Jacek Jassem's profile →
Citations per field
00.5×1.5×
Jacek Jassem · 1×
Citations per year

Countries citing papers authored by Danny Rischin

Since Specialization
Citations

This map shows the geographic impact of Danny Rischin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danny Rischin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danny Rischin more than expected).

Fields of papers citing papers by Danny Rischin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danny Rischin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danny Rischin. The network helps show where Danny Rischin may publish in the future.

Co-authors

The 25 scholars most cited alongside Danny Rischin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Danny Rischin Line = papers co-authored together Danny Rischin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 377 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Hit paper breakdown →
20032389
2
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
Hit paper breakdown →
2002683
3
Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial
Hit paper breakdown →
2010576
4
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
Hit paper breakdown →
2010554
5 2006418
6 2003352
7
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Hit paper breakdown →
2018343
8 2010276
9 2009269
10 2005247
11 1996223
12 2002217
13 2012198
14 2004196
15 2005183
16 2004174
17 2010171
18
Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline
Hit paper breakdown →
2018170
19 2001166
20 2001158

About Danny Rischin

Danny Rischin is a scholar working on Oncology, Otorhinolaryngology, Pulmonary and Respiratory Medicine, Epidemiology and Surgery, having authored 377 papers that have together received 15.6k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (106 papers), Cancer Immunotherapy and Biomarkers (53 papers), Nonmelanoma Skin Cancer Studies (39 papers), Lung Cancer Treatments and Mutations (28 papers), CAR-T cell therapy research (28 papers), Cancer Diagnosis and Treatment (24 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Cancer, Hypoxia, and Metabolism (19 papers). The work is most often cited by research in Otorhinolaryngology (3.2k citations), Oncology (5.7k citations), Pulmonary and Respiratory Medicine (4.6k citations), Cancer Research (1.8k citations) and Radiology, Nuclear Medicine and Imaging (1.5k citations). Danny Rischin has collaborated with scholars based in Australia, United States and Canada. Frequent co-authors include June Corry, Lester J. Peters, Rodney J. Hicks, Richard Fisher, Benjamin Solomon, Richard J. Young, A. Feyereislova, Sandro Porceddu, Steven D. Averbuch and José Baselga. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, International Journal of Radiation Oncology*Biology*Physics, Head & Neck and Oral Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact